The occurrence of treatment-related grade 3 adverse events ( four [ 16 % ] of 25 patients in the continuation group vs three [ 14 % ] of 21 in the interruption group ) and grade 4 adverse events ( one [ 4 % ] vs none ) was similar in both groups .